GSK plc has made a significant advancement in cancer treatment with the recent approval of Jemperli (dostarlimab) by the U.S. Food and Drug Administration (FDA). This approval marks Jemperli as the first and only immunotherapy for adults with stage II and III microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) locally advanced rectal cancer. The approval is particularly notable as it allows eligible patients to potentially avoid traditional treatments such as chemotherapy, radiation, and surgery.

The FDA's decision, announced on October 19, 2026, was based on data from the AZUR-1 trial, which demonstrated a clinically significant proportion of participants achieving sustained clinical complete responses. Tony Wood, GSK's Chief Scientific Officer, emphasized the importance of this approval, stating, “Today, Jemperli becomes the first and only approved immunotherapy for adults in the US with MSI-H/dMMR locally advanced rectal cancer.”

Background

GSK plc, a global biopharma company, specializes in pharmaceutical preparations, as indicated by its SIC code 2834. The company is publicly traded on the NYSE under the ticker GSK and on the OTC market as GLAXF. GSK aims to unite science, technology, and talent to advance healthcare solutions, focusing on various therapeutic areas including oncology.

What the Filing Says

The filing details that Jemperli has been approved under the FDA's accelerated approval pathway. The approval is based on the AZUR-1 trial results, which showed that 68% of evaluable patients achieved sustained clinical complete responses at 12 months. Additionally, no disease recurrences were reported among responders after a median follow-up of more than two years.

Impact

This approval may significantly affect patients with MSI-H/dMMR locally advanced rectal cancer, who traditionally face invasive treatments with lasting side effects. The possibility of avoiding chemotherapy and surgery represents a meaningful advance for patients and their families. Furthermore, this development could reshape treatment protocols within the pharmaceutical industry, influencing how cancer therapies are approached.

What's Next

The filing does not say what happens next.